Trial Profile
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Cyclobenzaprine (Primary)
- Indications Fibromyalgia
- Focus Adverse reactions
- Sponsors Tonix Pharmaceuticals Inc
- 19 Sep 2016 Status changed from recruiting to discontinued.
- 02 Nov 2015 New trial record